Accelerating nanodrug development in continuous flow systems using informed prediction models based on low-cost surrogate nanoparticles (arXiv: 2608.05761)
Scanned 9/11/2026
Install to Claude Code
npx -y skills add hiyenwong/ai_collection --skill arxiv-2608-05761-accelerating-nanodrug-development-in-continuous-fl --agent claude-codeInstalls into .claude/skills of the current project.
Are you the author of Arxiv 2608 05761 Accelerating Nanodrug Development In Continuous Fl?
Add the live security badge to your README — it updates automatically with every re-scan.
[](https://www.skillsdirectory.com/skills/hiyenwong-arxiv-2608-05761-accelerating-nanodrug-development-ai-collection)More formats (shields.io, HTML) on the badges page.
---
name: arxiv-2608-05761-accelerating-nanodrug-development-in-continuous-fl
description: 'Accelerating nanodrug development in continuous flow systems using informed prediction models based on low-cost surrogate nanoparticles (arXiv: 2608.05761)'
metadata:
{
"arxiv_id": "2608.05761",
"utility": 1.0,
"title": "Accelerating nanodrug development in continuous flow systems using informed prediction models based on low-cost surrogate nanoparticles",
"authors": "Unknown",
"url": "https://arxiv.org/abs/2608.05761"
}
---
# Accelerating nanodrug development in continuous flow systems using informed prediction models based on low-cost surrogate nanoparticles
**arXiv ID:** 2608.05761
**Authors:** Unknown
**URL:** https://arxiv.org/abs/2608.05761
**Utility Score:** 1.00
## Summary
This skill was automatically generated from the arXiv paper titled "Accelerating nanodrug development in continuous flow systems using informed prediction models based on low-cost surrogate nanoparticles" (ID: 2608.05761).
## Usage
This skill can be used to reference the paper's concepts, methodologies, or findings in agent workflows.
## References
- arXiv: https://arxiv.org/abs/2608.05761
Is this your skill, or is something wrong with this listing? Request removal or report an issue. Author removals are honored within 72 hours.
No comments yet. Be the first to comment!